AbbVie's Pharmacyclics files patent suit against BeiGene over BTK rival Brukinsa
Pharmacyclics is bringing its BTK battle to court.
The AbbVie unit filed suit against BeiGene on Tuesday, alleging the company’s competing blood cancer drug Brukinsa infringes on a new patent around Imbruvica.
The patent in question, dubbed ‘803, was issued on Tuesday, the same day Pharmacyclics filed its complaint in Delaware federal court. It covers methods for using a BTK inhibitor of certain chemical structure for chronic lymphocytic leukemia and small lymphocytic lymphoma.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.